Juvenile Idiopathic Arthritis (JIA) is a chronic inflammatory condition of childhood, frequently involving the hip joint and causing functional impairment. Hip scoring systems have been extensively used in adult rheumatology and orthopedic practice for evaluating disease activity and response to treatment. Their use in pediatric rheumatology is limited because of anatomical and developmental variations in children. This article examines the applicability, strengths, and weaknesses of current hip scoring systems in the assessment of hip involvement in JIA. In addition, we address the necessity for pediatric-specific adaptations and possible new frameworks to improve accuracy in clinical use.
Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic rheumatic disease of childhood, involving more than one joint, such as the hip. Involvement of the hip joint in JIA is a major predictor of long-term disability, which makes early and accurate assessment essential. There are several hip scoring systems available in adult medicine to assess structural and functional impairments, such as the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Hip Outcome Score (HOS). These systems were, however, designed mainly for adults and might not be directly translatable to children because of differences in development, differences in disease patterns, and functional measurements that do not match pediatric activity levels. The purpose of this review is to assess whether such scoring systems are useable in pediatric rheumatology and to identify areas where they may need to be amended or replaced.
Harris Hip Score (HHS): Originally designed to evaluate hip function following hip arthroplasty, the HHS measures pain, function, deformity, and range of motion. While useful in adult arthritis and post-surgical assessments, its reliance on activities such as stair climbing and daily walking may not be directly applicable to children with varying developmental stages.
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): Used primarily for osteoarthritis assessment, WOMAC focuses on pain, stiffness, and function. However, the scoring does not consider pediatric-specific factors such as growth-related changes and the impact of disease on school and play activities.
Hip Outcome Score (HOS): Commonly used in young adults with hip pathologies, HOS emphasizes sports and activity limitations. Though it captures high-functioning individuals better than some other tools, it still does not fully accommodate pediatric-specific limitations, particularly in children with severe JIA involvement.
Juvenile Arthritis Functional Assessment Report (JAFAR): One of the few pediatric-specific tools, JAFAR assesses overall joint function in JIA but lacks hip-specific measures, reducing its utility for targeted assessments.
Developmental Variability: Children's skeletal structures are continuously growing, making fixed scoring criteria challenging to apply across different age groups.
Activity-Based Scoring Limitations: Many adult scoring systems measure function based on walking, climbing, and sports activities, which may not be relevant for all children, particularly younger patients or those with severe disease.
Lack of Imaging Integration: While adult scoring systems often rely on radiographic evidence, pediatric assessments must also consider growth plate involvement and other developmental factors visible on MRI or ultrasound.
Pain Perception Differences: Children may underreport or overreport pain due to communication barriers, affecting the reliability of subjective pain scales within existing systems.
Functional Outcome Relevance: Daily life activities differ significantly between adults and children; for instance, school participation and playtime are more relevant metrics in children than work-related physical demands measured in adult tools.
Given these challenges, modifications to existing hip scoring systems are necessary to improve their applicability in pediatric rheumatology. Potential adaptations include:
Age-Adjusted Activity Scales: Incorporating age-appropriate activities such as running, jumping, and participation in school activities instead of work-related tasks.
Growth and Development Considerations: Adjusting scoring to reflect variations in skeletal maturity, including markers for growth disturbances.
Integration of Imaging Findings: Adding MRI or ultrasound-based scoring to capture inflammatory and structural changes specific to pediatric hip involvement in JIA.
Parental and Patient-Reported Outcomes: Including caregiver assessments to complement self-reported pain and function measures, especially for younger children.
Standardized Pediatric-Specific Functional Assessments: Developing a composite scoring system integrating validated pediatric tools like the Childhood Health Assessment Questionnaire (CHAQ) with hip-specific metrics.
Although current hip scoring systems offer valuable insights, they fall short of providing an optimal assessment framework for children with JIA. A pediatric-specific hip scoring system should:
Be adaptable across different age groups and developmental stages.
Incorporate validated functional assessments tailored to childhood activities.
Utilize imaging techniques relevant to pediatric pathology.
Include both clinician-assessed and patient-reported outcome measures.
Be sensitive to early disease detection and treatment response in JIA.
To close the gap, there is a need to research developing and validating a pediatric-specific hip scoring system. Future research needs to include multidisciplinary efforts between pediatric rheumatologists, orthopedic specialists, radiologists, and rehabilitation experts. Large-scale cohort studies on reliability and validity testing of adapted scoring systems need to be given top priority to establish sound clinical utility.
Involvement of the hips in Juvenile Idiopathic Arthritis has important implications for long-term outcomes and requires accurate assessment to allow early treatment and monitoring. Although adult scoring systems have been available, direct adaptation into pediatric practice is restricted by the differences in growth, function, and structure. Modifications specific to pediatric patients or the creation of a new, validated pediatric-specific hip scoring system would significantly allow pediatric rheumatologists to properly evaluate and manage JIA-related hip disease more effectively. It is hoped that future studies aim to develop a comprehensive and appropriate framework that would be able to direct treatment modalities and further enhance clinical results in children with JIA.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation